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Background and purpose 
Until now, carbon ion RT (CIRT) dose constraints for the optic nerve (ON) have only been validated and 
reported in the NIRS RBE-weighted dose (DNIRS). The aim of this work is to improve CNAO’s RBE-weighted 
dose (DLEM) constraints by analyzing institutional toxicity data and by relating it to DNIRS. 
Material and methods 
A total of 65 ONs from 38 patients treated with CIRT to the head and neck region in the period 2013-14 
were analyzed. The absorbed dose (DAbs) of the treatment plans was reproduced and subsequently both 
DLEM and DNIRS were applied, thus relating CNAO clinical toxicity to DNIRS. 
Results 
Median FU was 47 (26-67) months. Visual acuity was preserved for the 56 ONs in which the old 
constraints were respected. Three ONs developed visual decline at DLEM│1%≥71 Gy(RBE)/DLEM│20%≥68 
Gy(RBE), corresponding to DNIRS│1%≥68 Gy(RBE)/DNIRS│20%≥62 Gy(RBE). Dose recalculation revealed that 
NIRS constraints of DNIRS│1%≤40 Gy(RBE)/DNIRS│20%≤28 Gy(RBE) corresponded to DLEM│1%≤50 
Gy(RBE)/DLEM│20%≤40 Gy(RBE). Reoptimization of treatment plans with these new DLEM constraints 
showed that the dose distribution still complied with NIRS constraints when evaluated in DNIRS. However, 
due to uncertainties in the method, and to comply with the EQD2-based constraints used at GSI/HIT, a 
more moderate constraint relaxation to DLEM│1%≤45 Gy(RBE)/DLEM│20%≤37 Gy(RBE) has been implemented 
in CNAO clinical routine since October 2018. 
Conclusion 
New DLEM constraints for the ON were derived by analyzing CNAO toxicity data and by linking our results 
to the experience of NIRS and GSI/HIT. This work demonstrates the value of recalculating and reporting 







In order to optimize carbon ion radiotherapy (CIRT) there is a need to validate dose constraints for 
important organs at risk (OARs). For the optic nerve (ON), constraints have been validated by the 
National Institute of Radiobiological Sciences (NIRS, Japan) [1], in which the relative biological 
effectiveness (RBE) for CIRT has been predicted by the mixed beam model (RBENIRS) [2, 3], and have been 
reported as the NIRS RBE-weighted dose (DNIRS). The NIRS constraints are not immediately useful for 
European centers where the Local effect model I (RBELEM)[4, 5] is used, because comparative studies 
show that RBELEM can predict a 60% higher RBE in the entrance region of the beam [6], and 5-15% higher 
RBE in the spread-out Bragg peak [7-9], relative to RBENIRS. At the National Center of Oncological 
Hadrontherapy (CNAO, Italy) [10, 11], dose constraints for ONs complied nominally with the NIRS 
constraints: D1% ≤ 40 Gy(RBE) and D20% ≤ 28 Gy(RBE), although RBELEM is used in treatment plan 
optimization. This was a conservative approach, adopted at the beginning of clinical activity to minimize 
the risk of unexpected visual impairment due to lack of clinically validated RBELEM-weighted dose (DLEM) 
constraints.  The aim of this work was to improve CNAO’s ON dose constraints by analyzing institutional 
toxicity and by relating the results to the constraints validated by NIRS. 
Material and methods 
 
Patient selection 
We identified a total of 38 patients (65 ONs) who had been treated at CNAO in the period 2013-2014 
with CIRT to the head and neck region and who had: 
 at least 2 years of follow-up 
 maximum dose (DLEM|1%) > 20 Gy(RBE) to optic nerve 
 available records of visual acuity before and after CIRT 
and did not have: 
 radiotherapy before or after CIRT at CNAO 
 higher dose to the chiasm than to the optic nerve 
 preexisting visual impairment 
 development of visual impairment in the follow-up period due to other causes than radiation 




Carbon ion radiotherapy at CNAO 
All patients were treated to a prescribed DLEM of 68.8 or 70.4 Gy(RBE) in 16 fractions (4 fractions/week) 
using the syngo® RT Planning (Siemens Healthcare, Erlangen, Germany) treatment planning system (TPS). 
The patients were included in prospective protocols (CNAO S9/2012/C, CNAO S12/2012/C and CNAO 
S15/2012/C) approved by the regional ethics committee, and signed consent was required for 
participation. Dose constraints for the ONs and chiasm were DLEM│1% ≤ 40 Gy(RBE) and DLEM│20% ≤ 28 
Gy(RBE). A 2 mm margin was applied to the planning organ at risk volume (PRV) in which the dose 
constraints, for plan optimization purposes, were DLEM│1% ≤ 60 Gy(RBE) and DLEM│20% ≤ 40 Gy(RBE). 
Following the patient’s consent, the constraints could be exceeded if they prevented adequate dose 
coverage to the target volume, provided that the function of the contralateral ON was adequate and 
would be preserved.  
 
Follow-up 
Patients were followed at CNAO every 3rd month with a clinical examination and magnetic resonance 
imaging (MRI). If symptoms of visual defects were reported by the patient or detected on clinical 
examination, the patient was referred to an ophthalmologist for further investigations and diagnosis. 
Radiation induced optic neuropathy (RION) was scored according to the Optic Nerve Disorder term of the 
Common Terminology Criteria for Adverse Events version 4.03 (CTCAE) [12]. 
 
Recalculation to RBENIRS-weighted dose distributions 
The patients’ computer tomography (CT) image files, structure set files, dose files and plan files (DICOM 
files) were exported from syngo® TPS and imported to the matRad open source multimodality radiation 
TPS (https://e0404.github.io/matRad/) in which the absorbed dose (DAbs) and DLEM were reproduced. 
Dose volume histograms (DVHs) of targets and OARs were compared with the corresponding DVHs of the 
dose distribution from the syngo® TPS to ensure correct reproduction of both DAbs and DLEM (results not 
reported). Secondly, the RBENIRS was implemented in the matRad TPS code and DNIRS was derived from 
the exact same absorbed dose. This enabled a direct comparison of each patient’s DLEM and DNIRS based 
exclusively on the differences in the RBE modelling. 
 
Statistics and normal tissue complication probability (NTCP) modelling 
Differences in frequencies between cohorts were compared using Chi-Square test or Fischer’s exact test. 
Non-parametrical distributions were compared with the Mann-Whitney U-test, while normally 
distributed data were compared with the independent samples T-test. NTCP was calculated for 
5 
 
cumulative DVH variables D1%, D10%, D20% through D50% and were used to derive the dose that would 
result in 5% (TD5) and 50% (TD50) probability of RION according to the equation: 




where d is the RBE-weighted dose to x% of the ON volume and a and b are constants estimated to 
provide the best fit to the data set, using binary logistic regression. All statistical procedures were 
performed with the software IBM SPSS Statistics for Windows, Version 24.0 (IBM Corp., Armonk, NY, 
U.S.A.). All p-values were obtained from two-sided tests. P-values <0.05 were considered significant. 
Reoptimization of treatment plans with new set of constraints 
Finally, a subset of patients, in which the original constraints had caused inadequate dose coverage to 
the clinical target volume (CTV) in their original DLEM plan, was reoptimized with the RayStation® 7.0 TPS 
(RaySearch Laboratories AB, Stockholm, Sweden) (currently under commissioning at CNAO) applying 
RBELEM as RBE model and optimizing the plan with a new set of DLEM constraints, as proposed by this work 
(see Results).  Subsequently, also these plans were recalculated to DNIRS, to validate that the reoptimized 
ON DVHs still complied with the original NIRS constraints. 
A flow chart of the steps involved in our method is presented in Appendix A, Figure A.1. 
 
Results 
Patient and disease characteristics are presented in Table 1. Median follow-up time was 47 (range 26-67) 
months. Among the 38 patients and 65 ONs analyzed, toxicity did not occur in the 52 ONs in which the 
current constraints were respected.  Three patients developed unilateral RION (all CTCAE grade 4) at 
doses DLEM│1% ≥ 71 Gy(RBE)/ DNIRS│1% ≥ 68 Gy(RBE) and DLEM│20% ≥ 68 Gy (RBE)/ DNIRS│20% ≥ 62 Gy (RBE). In all 
these cases, the ON constraints were intentionally violated in order to achieve adequate dose coverage 
to the nearby tumor. RION was detected at 11, 29 and 42 months after completed CIRT. In addition to 
the 3 ONs that developed toxicity, the applied constraints were breached for 10 ONs with a median 
follow-up of 45 (range 26-50) months. When evaluating the DVHs with DNIRS, only 6 of these ONs still 
exceeded NIRS constraints. All individual ONs in both DLEM and DNIRS are presented in Figure 1, 
demonstrating that RBENIRS generally predicts lower RBE than RBELEM, resulting in the DVHs being shifted 
towards lower doses. Key dosimetric data are presented in Table 2.  
The relationship of DNIRS and DLEM for D1% and D20% is presented in Figure 2, showing that a DNIRS│1% of ≤ 40 
Gy(RBE) and a DNIRS│20% of ≤ 28 Gy(RBE) could approximately be translated into new CNAO constraints of 
DLEM│1%  ≤ 50 Gy(RBE) and DLEM│20% ≤ 40 Gy(RBE). These new constraints for DLEM are plotted as open red 
squares in Figure 1. As can be observed, the ONs that comply with the original NIRS constraints when 
their DVHs are evaluated in DNIRS, remain compliant with the new CNAO constraints when their DVHs are 
evaluated in DLEM. Likewise, the ONs that exceed the NIRS constraints when evaluated in DNIRS still exceed 
the new CNAO constraints when evaluated in DLEM.  
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The estimates of TD5 and TD50 for parameters D1%-D50%, and their relation to the same parameters 
from the dose constraint validation at NIRS [1] are presented in Table 3, showing a remarkable 
agreement of TD50 between NIRS and CNAO data in DNIRS, while estimates of TD5 are substantially higher 
when based on the CNAO data.  
The NIRS validation cohort consisted of 30 patients (54 ONs), in which visual impairment occurred in 9 
patients (11 ONs). All ON DVHs from this cohort are displayed in Figure 3 (black DVHs). The DVHs of the 
ONs developing toxicity in the CNAO cohort (in DNIRS) are superimposed in red, showing good agreement 
to the NIRS cohort in respect to the dose levels at which toxicity seems to develop. The figure also 
displays the TD50 and TD5 estimates from Table 3, demonstrating the coherency of TD50 values and the 
discrepancy in TD5 values between the cohorts. 
A subset of patients in which the current constraints hindered adequate dose coverage to the clinical 
target volume (CTV) was reoptimized applying the proposed new set of DLEM constraints, i.e. DLEM│1% ≤ 50 
Gy(RBE) and DLEM│20% ≤ 40 Gy(RBE). After recalculation of the new plan to DNIRS, the ON DVHs consistently 
remained compliant to the original NIRS constraints. The dose distributions of a representative patient, 
in which the right ON needed to be spared in order to avoid bilateral blindness, are shown in Figure 4. 
The conservative constraints applied in the original plan inevitably resulted in inadequate dose coverage 
to the part of the CTV adjacent to the right ON (Figure 4A). Post hoc recalculation of the plan to DNIRS 
(Figure 4B) suggests that the right ON was excessively spared relative to the NIRS validated constraints. 
Reoptimizing the plan with the new DLEM constraints significantly improves CTV coverage (Figures 4C-D 
vs. Figures 4A-B) while maintaining compliance with the NIRS validated constraints in respect to DNIRS 
(Figure 4D). In this patient, the reoptimized plan achieved a dose coverage in which 99% of the 
prescribed dose covered 92% of the CTV and 95% of the prescribed dose covered 97.7% of the CTV. The 
respective dose coverage to the CTV of the original plan was only 82% and 93.2%.  
Discussion 
Due to the many uncertainties involved in the prediction of the RBE of CIRT, there will inevitably be 
substantial uncertainties related to the extrapolation of OAR constraints from the experience of photon 
RT. Therefore, the strategy of CNAO has been to define OAR constraints for CIRT based on CIRT clinical 
data. To date, there is a general lack of validated constraints for most OARs. The few publications 
addressing this topic have all reported the dose statistics and NTCPs solely in the respective institutional 
RBE-weighted dose [1, 13-18], thus making them incomprehensible to institutions applying a different 
RBE model. 
The aim of this work was first and foremost to establish less conservative constraints for the ON which 
could be used at CNAO for a 16 fraction CIRT treatment in which RBELEM is applied. Our data show that 
the original constraints have been conservative, resulting in no unanticipated toxic events and with a 
seemingly large buffer zone separating these constraints and the dose levels where toxicity was 
observed. In NTCP modelling, we found TD50 to agree well with the published TD50 estimates at NIRS, 
while there was a discrepancy in TD5 estimates. This discrepancy is probably a result of a scarcity of 
observations in the CNAO cohort in the middle- to high doses, relative to the NIRS cohort, which is 
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evident when comparing the neatly scattered DVHs of Figure 3 (NIRS DVHs) to the DVHs of Figure 1 
(CNAO DVHs) which are clustered at lower doses. As a consequence the TD5 estimates of the CNAO data 
may be unreliable. However, by recalculating our data to DNIRS, it was possible to translate the 
constraints validated at NIRS into DLEM and thereby propose new CNAO constraints to be evaluated for 
feasibility. As shown in Results, new CNAO constraints of DLEM│1% ≤ 50 Gy(RBE) and DLEM│20% ≤ 40 Gy(RBE) 
seem to correspond well with the NIRS validated constraints.  
It should be noted that this approach assumes a perfect agreement between the DNIRS recalculated for 
our cohort, and the DNIRS reported for the validation cohort at NIRS. This may not be correct, since the 
CIRT at NIRS is delivered by a passive scattering system and with a different beam model calculating the 
underlying absorbed dose. It has been shown that the absorbed dose of a given RBE-weighted dose 
could on average vary about 2.5% in the target region of head and neck treatments, depending on the 
beam model [8]. Differences in out-of-target areas have not been described in detail, but one might 
expect to find similar or even more profound deviations in absorbed dose especially within the lateral 
penumbra dose fall-off. This region is indeed very sensitive to how the lateral spread of the beam is 
modelled. This is of importance, since the sharp lateral penumbra of the carbon ion beam typically is 
utilized to avoid high doses to optic nerves located close to the tumor.  
Therefore, it is also valuable to relate our proposed new constraints to the traditions of GSI 
Helmholtzzentrum für Schwerionenforschung (GSI), Darmstadt, Germany, later adapted at the Heidelberg 
Ion-Beam Therapy center (HIT), Heidelberg, Germany [19], which together are Europe’s most 
experienced heavy ion therapy center. Their ON constraint has been a maximum dose (DLEM│max) of ≤ 54 
Gy(RBE), expressed as the biologically equivalent dose in 2 Gy(RBE) fractions (EQD2), applying α/β = 2 Gy 
[20]. Although GSI/HIT, as CNAO, applies both active scanning beam delivery and the RBELEM as their RBE 
model, direct comparison to CNAO is hampered by a difference in fractionation scheme. Typically, HIT 
uses 20 fractions of 3 Gy(RBE) delivered within 3-3.5 weeks [20, 21], while CNAO uses 16 fractions of 4.3-
4.4 Gy(RBE) delivered within 4 weeks. Unfortunately, a validation of the GSI/HIT constraint has not yet 
been published. However, of interest is their published observation of a patient developing bilateral 
blindness after receiving a nominal DLEM│max of 54 Gy(RBE) to the optic pathways, corresponding to an 
EQD2 of 63 Gy(RBE) [20]. This raises concern that our proposed new CNAO constraint of DLEM│1% ≤ 50 
Gy(RBE) might be too high, since it converts into an EQD2 of as much as 64 Gy(RBE). Although the 
application of EQD2 and the use of α/β = 2 Gy for optic pathways is supported by the European Particle 
Therapy Network (EPTN) also for proton RT [22], this method may not be sufficiently precise for CIRT, 
due to the greater uncertainties involved in RBE prediction. However, to our knowledge this approach 
has been implemented without unanticipated toxicity at GSI/HIT, thus supporting the feasibility of using 
EQD2 conversion within an institution applying RBELEM. Accordingly, within the 16 fraction regimen at 
CNAO, an EQD2 constraint of ≤ 54 Gy(RBE) corresponds to a nominal DLEM│1% to the ON of ≤ 45 Gy(RBE), 
and implies a 9% reduction relative to the initial proposal of DLEM│1% ≤ 50 Gy(RBE). A proportionately 
equal reduction of the proposed DLEM│20% constraint results in DLEM│20% ≤ 37 Gy(RBE). 
Regardless of the validity of EQD2 for CIRT, a reduction in the initially proposed new CNAO constraints 
mitigates the uncertainties involved in our DLEM to DNIRS translation, and is therefore a reasonable first 
step for dose constraint relaxation at CNAO. As a consequence of the results and deliberations presented 
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in this paper, new ON constraints of DLEM│1% ≤ 45 Gy(RBE) and DLEM│20% ≤ 37 Gy(RBE) have been 
implemented at CNAO since October 2018.  
This paper demonstrates the value of assessing and reporting data on CIRT clinical toxicity in both the 
institution’s native RBE model and the alternative model which is widely used clinically. To date, dose 
recalculation has been a cumbersome affair, but we anticipate that the introduction of such functionality 
in commercial TPS’ within the next years will facilitate this process. We therefore hope that future 
publications will report OAR dose statistics and NTCPs in both DNIRS and DLEM, and thus accelerate the 
much needed validation of OAR constraints for both RBE models. 
We have derived new and safe dose constraints for the ON to be used at CNAO by analyzing the available 
institutional data and by mitigating the uncertainties caused by a rather small sample size linking our 
results to the experience and traditions of NIRS and GSI/HIT. This work also demonstrates how valuable 
and much needed dose-response data can be saved from being lost in translation between Japanese and 
European CIRT institutions by recalculating and reporting results in both clinically applied RBE models.  
 
 
Table 1 Patient and disease characteristics     
    All (n=38) RION=Y (n=3) RION=N (n=35) 
Sex, female:male 18:20 2:1 16:19 
Median age (range), y 59 (16-81) 62 (54-68) 54 (16-81) 
Comorbidity, n (%)       
  Hypertension 9 (23.7%) 1 (33.3%) 8 (22.9%) 
  Diabetes mellitus 8 (21.1%) 1 (33.3%) 7 (20.0%) 
  Cardiovascular disease 4 (10.5%) 1 (33.3%) 3 (8.6%) 
Histology, n (%)       
  Adenoid cystic carcinoma 14 (36.8%) 2 (66.7%) 12 (34.3%) 
  Chordoma 14 (36.8%) 0 (0.0%) 14 (40.0%) 
  Chondrosarcoma 3 (7.9%) 0 (0.0%) 3 (8.6%) 
  Other sarcoma 5 (13.2%) 1 (33.3%) 4 (11.4%) 
  Acinar cell carcinoma 1 (2.6%) 0 (0.0%) 1 (2.9%) 
  Mucosal malignant melanoma 1 (2.6%) 0 (0.0%) 1 (2.9%) 
Site, n (%)       
  Clivus 12 (31.6%) 1 (33.3%) 11 (31.4%) 
  Paranasal sinus 9 (23.7%) 2 (66.7%) 7 (20.0%) 
  Skull base 9 (23.7%) 0 (0.0%) 9 (25.7%) 
  Nasal cavity 4 (10.5%) 0 (0.0%) 4 (11.4%) 
  Nasopharynx 2 (5.2%) 0 (0.0%) 2 (5.7%) 




Table 2: Dose statistics for all ONs and/or grouped by ONs that developed (RION=yes) or did not develop 
(RION=no) radiation induced optic neuropathy. P values represent the significance level for the observed 















         
    All (n=65) RION=yes (n=3) RION=no (n=62)  P value 
Median ON volume (range), cm3 0.92 (0.45-1.52) 0.74 (0.46-1.34) 0.94 (0.45-1.52) 0.485 
D1%, median (range)         
  DLEM, Gy (RBE)   71.6 (70.7-78.6) 28.4 (12.2-73.6) <0.001 
  DNIRS, Gy (RBE)   67.2 (66.3-79.3) 18.1 (6.1-76.2) <0.001 
D10%, median (range)         
  DLEM, Gy (RBE)   70.8 (69.1-72.5) 22.9 (6.5-71.8) <0.001 
  DNIRS, Gy (RBE)   65.2 (63.8-70.0) 12.8 (3.0-71.8) <0.001 
D20%, median (range)         
  DLEM, Gy (RBE))   68.5 (68.1-70.5) 19.5 (0.7-71.4) <0.001 
  DNIRS, Gy (RBE)   63.0 (61.8-64.7) 10.2 (0.2-68.2) <0.001 
D30%, median (range)         
  DLEM, Gy (RBE)   68.1 (62.6-70,1) 17.1 (0.2-71.1) <0.001 
  DNIRS, Gy (RBE)   62.2 (54.6-64.2) 8.4 (0.0-66.7) <0.001 
D50%, median (range)         
  DLEM, Gy (RBE)   67.4 (56.1-69.3) 12.6 (0.1-70.7) <0.001 
      
  DNIRS, Gy (RBE)   60.4 (47.3-62.6) 5.6 (0.0-65.4) <0.001 
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Table 3: TD5 and TD50 values for optic nerve DVH parameters as derived from the present study (CNAO), 
presented in DLEM and DNIRS, compared to corresponding values reported by Hasegawa et al. [1] (NIRS). 
    CNAO   NIRS   CNAO/NIRS-1  
(DNIRS)     DLEM   DNIRS   DNIRSª   
TD5, Gy(RBE) D1% 62   49   n.s.     
  D10% 61   45   30*   50,0 % 
  D20% 55   42   28*   50,0 % 
  D30% 47   37   24*   54,2 % 
  D50% 41   30   12*   150,0 % 
TD50, Gy(RBE) D1% 71   68   n.s.     
  D10% 69   63   63   0,0 % 
  D20% 66   60   60*   0,0 % 
  D30% 64   57   59   -3,4 % 
  D50% 61   53   51   3,9 % 
n.s. = not specified. ªDoses as reported in Hasegawa et al. [1]. *Approximated from 
















Figure 1: Cumulative DVH of all 65 ONs in DLEM (upper panel) and DNIRS (lower panel). Dashed DVH-lines 
represents optic nerves that developed RION. Red, filled squares indicate the current dose constraints of 
D1% ≤ 40 Gy(RBE) and D20% ≤ 28 Gy(RBE). Red, open squares in upper panel represents possible new DLEM 




















































Figure 2: Relationship of DNIRS and DLEM for D1% (blue circles) and D20% (red circles) with corresponding 























































Figure 3: Reprint of Fig 4a from Hasegawa et al. [1] showing the DVHs from the NIRS validation cohort, 
where black DVHs represent ONs that developed RION, and grey DVHs represent ONs that did not 
develop RION. Superimposed on the figure are the DNIRS DVHs (red) of the three ONs from the CNAO 
cohort that developed RION, TD5 (orange) and TD50 (yellow) of NIRS cohort (triangles) and CNAO cohort 








































Figure 4: Original and reoptimized plan in DLEM and DNIRS, demonstrating improved CTV (blue contour) 
dose coverage when applying the new DLEM constraints (Fig. 4c) to the right ON (orange contour) and 
maintained compliance to original NIRS constraints after recalculation to DNIRS (Fig. 4d). Legend for dose 
distribution in Gy(RBE): dark blue=30-35; light blue=35-40; light green=40-50; dark green=50-55; 










































































  Reoptimized DLEM 
plans with new DLEM 
constraints 
 Plans recalculated    
to DNIRS to confirm 
compliance with 
NIRS DNIRS constraints 
Figure A.1: Process of recalculation of RBE-weighted dose and proposal of new CNAO 
constraints. DICOM files from the original treatment plans were imported to the matRad 
TPS. The absorbed dose (DAbs) and RBE-weighted dose distributions (DLEM and DNIRS) were 
recalculated. Correct reproduction of DAbs and DLEM compared to the original plans was 
confirmed. The recalculated DLEM and DNIRS were used for data analysis, in which new DLEM 
constraints were proposed. Treatment plans were reoptimized with DLEM in the Raystation 
TPS applying the new DLEM constraints. Subsequently, these new plans were recalculated 
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